콘텐츠로 건너뛰기
Merck

주요 문서

모든 문서 보기

SML1581

Moxifloxacin hydrochloride

98.0 to 102.0% (HPLC)

동의어(들):

12-8039, Avalox, BAY12-8039, 1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydropyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride

조직 및 계약 가격을 보려면 로그인를 클릭합니다.

크기 선택

보기 변경

제품정보 (DICE 배송 시 비용 별도)

실험식(Hill 표기법):
C21H24FN3O4· HCl
CAS 번호:
186826-86-8
Molecular Weight:
437.89
NACRES:
NA.77
PubChem Substance ID:
329825971
UNSPSC Code:
12352200
MDL number:
MFCD00949117
Beilstein/REAXYS Number:
8377447
Assay:
98-102% (HPLC)
Form:
powder
Quality level:
100
Storage condition:
desiccated
기술 서비스
도움이 필요하신가요? 저희 숙련된 과학자 팀이 도와드리겠습니다.
도움 문의

제품 이름

Moxifloxacin hydrochloride, 98-102% (HPLC)

Quality Level

100

assay

98-102% (HPLC)

form

powder

storage condition

desiccated

color

light yellow to yellow

solubility

H2O: slightly soluble

storage temp.

−20°C

SMILES string

Cl.COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc4C(=O)C(=CN(C5CC5)c14)C(O)=O

InChI

1S/C21H24FN3O4.ClH/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24;/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28);1H/t11-,16+;/m0./s1

InChI key

IDIIJJHBXUESQI-DFIJPDEKSA-N

유사한 제품을 찾으십니까? 방문 제품 비교 안내

관련 카테고리

General description

Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial. Moxifloxacin is a 8-methoxy quinolone and differs from other quinolones.

Application

Moxifloxacin hydrochloride has been used to study its antibacterial action against bacteria that have grown to high density.

Biochem/physiol Actions

Moxifloxacin has proved to be effective in treating sinusitis, community-acquired respiratory tract infection, pneumonia and acute exacerbations of chronic bronchitis. It has improved anti-gram positive activity compared to other fluoroquinolone such as ciprofloxacin and ofloxacin. Moxifloxacin is useful in treating skin infections that is of bacterial origin. It is known to have proper penetration into peripheral tissues and inflammatory fluids. Fluoroquinolones stabilize DNA strand breaks created by DNA gyrase and topoisomerase IV by binding to the enzyme-DNA complex. Compared to mammalian DNA gyrase, moxifloxacin has 100 times higher affinity for bacterial DNA gyrase. Moxifloxacin is an antibiotic and works against both Gram-positive and Gram-negative bacteria. Moxifloxacin is being investigated for the treatment of multidrug-resistant tuberculosis.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 3 - Eye Irrit. 2

저장 등급

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 문서 section.

도움이 필요하시면 연락하세요. 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Edward D Chan et al.
American journal of respiratory and critical care medicine, 169(10), 1103-1109 (2004-01-27)
Multidrug-resistant tuberculosis, a disease caused by Mycobacterium tuberculosis strains that are resistant at least to rifampin and isoniazid, entails extended treatment, expensive and toxic regimens, and higher rates of treatment failure and death. We retrospectively analyzed the outcomes in 205
An HPLC Method for the Determination of Moxifloxacin in Breast Milk by Fluorimetric Detection with Precolumn Derivatization.
Tekkeli SEK
Acta Chromatographica , 10-10 (2016)
Moxifloxacin.
Muijsers R B and Jarvis B
Drugs, 62(6), 967-973 (2002)
Stephen H Gillespie
European respiratory review : an official journal of the European Respiratory Society, 25(139), 19-28 (2016-03-02)
Tuberculosis (TB) remains a global threat with more than 9 million new infections. Treatment remains difficult and there has been no change in the duration of the standard regimen since the early 1980s. Moreover, many patients are unable to tolerate
Francis S Mah
Current opinion in ophthalmology, 15(4), 316-320 (2004-07-03)
The fourth-generation fluoroquinolones, moxifloxacin and gatifloxacin, were introduced in 2003 promising improved spectrum of activity and delayed development of resistance. Although these topical agents have recently been introduced in commercial form, there is already a growing body of evidence showing
모든 관련된 서류 보기

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.